Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Characteristics of patients at baseline and after 6 months of treatment

From: Effects of a new nutraceutical combination on cognitive function in hypertensive patients

  Baseline 6-months Treatment effecta
SBP (mmHg)    
 Control group 133.3 ± 16.9 133.1 ± 15.7 0.132
 Active treatment group 135.6 ± 13.5 130.6 ± 11.4
DBP (mmHg)    
 Control group 84.1 ± 12.3 83.1 ± 8.8 0.402
 Active treatment group 85.8 ± 9.1 81.5 ± 8.5
Heart rate (bpm)    
 Control group 68.8 ± 6.8 68.2 ± 5.3 0.209
 Active treatment group 66.4 ± 7.9 68.3 ± 8.3
Total cholesterol (mg/dl)    
 Control group 198.2 ± 23.7 210.8 ± 21.7 0.132
 Active treatment group 201.9 ± 27.5 204.4 ± 23.6
HDL cholesterol (mg/dl)    
 Control group 47.6 ± 7.9 51.3 ± 11.9 0.740
 Active treatment group 51.3 ± 7.2 54.3 ± 7.7
LDL cholesterol (mg/dl)    
 Control group 129.2 ± 26.1 138.9 ± 22.4 0.179
 Active treatment group 126.7 ± 30.4 126.9 ± 25.0
Triglycerides (mg/dl)    
 Control group 107.1 ± 34.8 103.1 ± 35.0 0.946
 Active treatment group 119.5 ± 27.9 115.9 ± 24.3
Glycaemia (mg/dl)    
 Control group 95.7 ± 11.2 96.6 ± 13.3 0.746
 Active treatment group 93.1 ± 7.5 93.0 ± 8.0
Augmentation Index (%)    
 Control group 14.19 ± 10.00 14.69 ± 11.79 0.028
 Active treatment group 18.59 ± 18.21 12.24 ± 12.30
  1. Values are means ± standard deviation
  2. SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein
  3. a = active treatment versus placebo, GLM analysis